Kos Biotechnology Partners

Kos Biotechnology Partners is a private life sciences venture capital and investment firm focused on backing companies across biotech and related healthcare subsectors rather than developing its own therapeutics. The firm positions itself as the first Greece-based venture capital firm dedicated to life sciences and operates with a transatlantic strategy linking the U.S. biopharma ecosystem with Europe. Kos invests from company formation through Series C, with stated focus areas including novel therapeutics, pharmaceutical services, and technology-enabled life sciences platforms. The firm is headquartered across New York and Athens and was founded by Dr. Simos Simeonidis and Alex Tzoukas, with Nikos Kostaras as a partner. As of June 2026, Kos reported $123 million in capital commitments for its inaugural global life sciences fund.